Abstract:AIM: To investigate the clinical effects of laser photocoagulation combined with anti-vascular endothelial growth factor(VEGF)drugs at different time in the treatment of diabetic retinopathy(DR).METHODS: A prospective study was conducted. Totally 120 patients(191 diseased eyes)with DR who were admitted to the hospital between January 2018 and January 2019 were divided into group A(treated with simple laser photocoagulation, 30 cases, 44 diseased eyes), group B(treated with intravitreal injection of ranibizumab, 30 cases, 46 diseased eyes), group C(treated with intravitreal injection of ranibizumab after laser photocoagulation, 30 cases, 49 diseased eyes)and group D(treated with laser photocoagulation after intravitreal injection of ranibizumab, 30 cases, 52 diseased eyes). Patients in each group were followed up for 6mo after the end of treatment. The best corrected visual acuity(BCVA), intraocular pressure and central foveal thickness(CMT)of each group were compared before and after treatment. The situation of laser photocoagulation and anti-VEGF treatment, complications and recurrence of diabetic macular edema were observed.RESULTS: There was no significant difference in BCVA or CMT among the four groups before treatment(P>0.05). The two indexes were improved at 1wk, 1mo, 3mo and 6mo after treatment(P<0.05). Besides, they were better in group C and group D than in group A and group B at different time after treatment(P<0.05). The BCVA and CMT in group D were better than those in group C at 1wk, 1mo and 3mo after surgery(P<0.05). There was no significant difference in intraocular pressure among the four groups before or after treatment(P>0.05). The laser parameters and frequency of laser treatment were lower or fewer in group C and group D than in group A, and lower in group D than in group C(P<0.05). The frequencies of intravitreal injection in group C and group D were fewer than that in group B(P<0.05). There was no significant difference in the frequency of laser treatment or drug injection between groups C and group D(P>0.05). There was no significant difference in the incidence of complications or the incidence of diabetic macular edema among the four groups during follow up(P>0.05).CONCLUSION: The effect of laser photocoagulation after intravitreal injection of anti-VEGF drug is better than simple photocoagulation, simple intravitreal injection or intravitreal injection of ranibizumab after laser photocoagulation in the treatment of DR. It can improve the BCVA, relieve macular edema, reduce laser energy, frequency of laser treatment and injection frequency of anti-VEGF drug, with safety.

[Effects of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Drugs on Ocular Blood Vessels and Blood Flow in Patients with Diabetic Retinopathy].

Changes in Vitreous VEGF, Bfgf and Fibrosis in Proliferative Diabetic Retinopathy after Intravitreal Bevacizumab.

Inflammatory Machenism in the Pathogenesis of Diabetic Retinopathy

Effects of intravitreal injection of anti-vascular endothelial growth factor drugs on retinal blood circulation

Clinical Research Progress of Anti-Vegf Agents for Diabetic Retinopathy

Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?

Effect of Anti-VEGF drugs on diabetic Retinopathy-Microaneurysms: A correlation study

[The Rational Use of Anti-Vascular Endothelial Growth Factor Drugs to Assist the Treatment of Diabetic Retinopathy].

Molecules related to diabetic retinopathy in the vitreous and involved pathways

Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy

Update on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy

Recent advances in the treatment and delivery system of diabetic retinopathy

Research Progress on Drugs Used for the Anti-Vascular Endothelial Growth Factor Drugs in the Treatment of Diabetic Retinopathy

Effects of Laser Photocoagulation Combined with Anti-Vegf Drugs at Different Time in the Treatment of Diabetic Retinopathy

Study on the effects of different anti-VEGF drugs on fibrovascular membranes of proliferative diabetic retinopathy

VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy

Vascular Endothelial Growth Factor and Diabetic Retinal Disease

Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature

The Use of Vascular Endothelial Growth Factor Inhibitors in Patients with Proliferative Diabetic Retinopathy

Blockade of Vascular Endothelial Growth Factor Receptor 1 Prevents Inflammation and Vascular Leakage in Diabetic Retinopathy.

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy